ADVANCED PHARMACOLOGY - NR566
EXAM 1 (LATEST 2026/ 2027 UPDATE)
QUESTIONS AND 100% CORRECT
VERIFIED ANSWERS| GRADE A+
1. A patient with chronic kidney disease requires a drug that is primarily excreted by the
kidneys. Which adjustment should the prescriber expect to make to minimize toxicity?
A. Increase the dosage of the drug.
B. Decrease the dosing interval.
C. Change to an oral route for slower absorption.
D. Decrease the dosage of the drug.
Answer: D
Conceptual Explanation: In patients with renal impairment, drug excretion is reduced,
leading to potential accumulation. Reducing the dosage or increasing the dosing interval is
necessary to prevent toxicity.
2. Which statement best describes the ‘First-Pass Effect’?
A. The rapid renal excretion of a drug after its first cycle through the blood.
B. The initial binding of a drug to plasma albumin.
C. The inactivation of a drug by liver enzymes before it reaches systemic circulation.
,D. The movement of a drug from the site of administration to the blood.
Answer: C
Conceptual Explanation: The first-pass effect refers to the rapid hepatic metabolism of
certain oral drugs, which can significantly reduce the amount of active drug reaching the
systemic circulation.
3. A 75-year-old patient is prescribed a lipid-soluble drug. Which age-related physiological
change should the clinician consider regarding this drug’s distribution?
A. Decreased total body water.
B. Reduced serum albumin levels.
C. Increased percentage of body fat.
D. Increased hepatic blood flow.
Answer: C
Conceptual Explanation: Older adults have an increased percentage of body fat, which
increases the volume of distribution for lipid-soluble drugs, potentially prolonging their
half-life.
4. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of all
prescribed drugs?
A. CYP1A2
B. CYP3A4
, C. CYP2D6
D. CYP2C9
Answer: B
Conceptual Explanation: CYP3A4 is the most abundant CYP enzyme in the liver and is
responsible for the metabolism of about half of the drugs currently on the market.
5. A patient is taking a drug that is a known CYP450 inducer. What effect will this have on a
co-administered drug that is a substrate of the same enzyme?
A. Increased plasma levels of the substrate drug.
B. Decreased metabolism of the substrate drug.
C. No change in the substrate drug’s concentration.
D. Decreased plasma levels of the substrate drug.
Answer: D
Conceptual Explanation: Inducers increase the synthesis of CYP enzymes, which
accelerates the metabolism of substrate drugs, thereby decreasing their plasma
concentrations.
6. Why are infants more sensitive to drugs that affect the Central Nervous System (CNS)?
A. Infants have a more permeable blood-brain barrier.
B. Infants have higher gastric acidity.
C. Infants have increased protein binding sites.
EXAM 1 (LATEST 2026/ 2027 UPDATE)
QUESTIONS AND 100% CORRECT
VERIFIED ANSWERS| GRADE A+
1. A patient with chronic kidney disease requires a drug that is primarily excreted by the
kidneys. Which adjustment should the prescriber expect to make to minimize toxicity?
A. Increase the dosage of the drug.
B. Decrease the dosing interval.
C. Change to an oral route for slower absorption.
D. Decrease the dosage of the drug.
Answer: D
Conceptual Explanation: In patients with renal impairment, drug excretion is reduced,
leading to potential accumulation. Reducing the dosage or increasing the dosing interval is
necessary to prevent toxicity.
2. Which statement best describes the ‘First-Pass Effect’?
A. The rapid renal excretion of a drug after its first cycle through the blood.
B. The initial binding of a drug to plasma albumin.
C. The inactivation of a drug by liver enzymes before it reaches systemic circulation.
,D. The movement of a drug from the site of administration to the blood.
Answer: C
Conceptual Explanation: The first-pass effect refers to the rapid hepatic metabolism of
certain oral drugs, which can significantly reduce the amount of active drug reaching the
systemic circulation.
3. A 75-year-old patient is prescribed a lipid-soluble drug. Which age-related physiological
change should the clinician consider regarding this drug’s distribution?
A. Decreased total body water.
B. Reduced serum albumin levels.
C. Increased percentage of body fat.
D. Increased hepatic blood flow.
Answer: C
Conceptual Explanation: Older adults have an increased percentage of body fat, which
increases the volume of distribution for lipid-soluble drugs, potentially prolonging their
half-life.
4. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of all
prescribed drugs?
A. CYP1A2
B. CYP3A4
, C. CYP2D6
D. CYP2C9
Answer: B
Conceptual Explanation: CYP3A4 is the most abundant CYP enzyme in the liver and is
responsible for the metabolism of about half of the drugs currently on the market.
5. A patient is taking a drug that is a known CYP450 inducer. What effect will this have on a
co-administered drug that is a substrate of the same enzyme?
A. Increased plasma levels of the substrate drug.
B. Decreased metabolism of the substrate drug.
C. No change in the substrate drug’s concentration.
D. Decreased plasma levels of the substrate drug.
Answer: D
Conceptual Explanation: Inducers increase the synthesis of CYP enzymes, which
accelerates the metabolism of substrate drugs, thereby decreasing their plasma
concentrations.
6. Why are infants more sensitive to drugs that affect the Central Nervous System (CNS)?
A. Infants have a more permeable blood-brain barrier.
B. Infants have higher gastric acidity.
C. Infants have increased protein binding sites.
